These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


174 related items for PubMed ID: 39320645

  • 1. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Michaeli JC, Michaeli T, Trapani D, Albers S, Dannehl D, Würstlein R, Michaeli DT.
    Breast Cancer; 2024 Nov; 31(6):1144-1155. PubMed ID: 39320645
    [Abstract] [Full Text] [Related]

  • 2. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
    Michaeli DT, Michaeli T.
    J Natl Compr Canc Netw; 2024 Apr 22; 22(4):. PubMed ID: 38648855
    [Abstract] [Full Text] [Related]

  • 3. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
    Michaeli DT, Michaeli T.
    J Clin Oncol; 2022 Dec 10; 40(35):4095-4106. PubMed ID: 35921606
    [Abstract] [Full Text] [Related]

  • 4. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC.
    Eur J Health Econ; 2024 Aug 10; 25(6):979-997. PubMed ID: 37962724
    [Abstract] [Full Text] [Related]

  • 5. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
    He Q, Li Q, Lv F, Kaitin KI, Shao L.
    Ther Innov Regul Sci; 2021 Jul 10; 55(4):676-684. PubMed ID: 33683659
    [Abstract] [Full Text] [Related]

  • 6. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T, Jürges H, Michaeli DT.
    BMJ; 2023 May 09; 381():e073242. PubMed ID: 37160306
    [Abstract] [Full Text] [Related]

  • 7. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.
    Michaeli DT, Michaeli T, Albers S, Michaeli JC.
    J Natl Cancer Inst; 2024 Feb 08; 116(2):216-229. PubMed ID: 37824202
    [Abstract] [Full Text] [Related]

  • 8. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG.
    JAMA Netw Open; 2020 Nov 02; 3(11):e2024406. PubMed ID: 33170262
    [Abstract] [Full Text] [Related]

  • 9. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
    Michaeli DT, Michaeli T.
    Value Health; 2023 Nov 02; 26(11):1590-1600. PubMed ID: 37516196
    [Abstract] [Full Text] [Related]

  • 10. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
    Tibau A, Hwang TJ, Molto C, Avorn J, Kesselheim AS.
    JAMA Oncol; 2024 May 01; 10(5):634-641. PubMed ID: 38573645
    [Abstract] [Full Text] [Related]

  • 11. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P.
    Invest New Drugs; 2022 Aug 01; 40(4):798-809. PubMed ID: 35389145
    [Abstract] [Full Text] [Related]

  • 12. Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024.
    Luo X, Du X, Lv X, Yang Y, Zhang X, Huang L.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2439080. PubMed ID: 39412805
    [Abstract] [Full Text] [Related]

  • 13. Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.
    Michaeli DT, Michaeli T, Albers S, Michaeli JC.
    Target Oncol; 2024 Sep 01; 19(5):797-809. PubMed ID: 39085451
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.
    Michaeli DT, Michaeli T, Albers S, Michaeli JC.
    BMJ Evid Based Med; 2024 Sep 20; 29(5):333-341. PubMed ID: 38760158
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C, Hwang TJ, Borrell M, Andres M, Gich I, Barnadas A, Amir E, Kesselheim AS, Tibau A.
    Cancer; 2020 Oct 01; 126(19):4390-4399. PubMed ID: 32697362
    [Abstract] [Full Text] [Related]

  • 16. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY, Raghunathan V, Prasad V.
    JAMA Intern Med; 2019 Jul 01; 179(7):915-921. PubMed ID: 31135822
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.